Physician profile
Wasae S Tabibi
NPI 1255336012
$5,252.14
in general payments reported to CMS, 2019-2025
27 companies · $943 in 2025
The $943 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,212 · 2020: $929 · 2021: $256 · 2022: $268 · 2023: $431 · 2024: $1,212 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,544 · Education: $41.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,544.21 |
| Education | $41.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $831.43 | 2019-2025 | Jynarque |
| Horizon Therapeutics Plc | $668.57 | 2019-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $634.93 | 2019-2025 | Rayaldee |
| Akebia Therapeutics INC | $495.50 | 2019-2025 | Vafseo, Auryxia |
| Amgen INC. | $463.05 | 2019-2024 | Krystexxa, Tavneos |
| Vifor Pharma, INC. | $424.70 | 2019-2024 | Veltassa |
| Novartis Pharmaceuticals Corporation | $320.63 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $263.51 | 2020-2025 | Terlivaz |
| Calliditas Therapeutics US INC. | $149.66 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $146.33 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $135.54 | 2019 | |
| Ardelyx, INC. | $132.97 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $109.86 | 2020-2023 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $80.24 | 2023-2024 | Farxiga, Lokelma |
| Lilly USA, LLC | $70.80 | 2024-2025 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $46.76 | 2024 | |
| Globus Medical, INC. | $45.42 | 2025 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.82 | 2024-2025 | Jardiance |
| Daiichi Sankyo INC. | $40.26 | 2024-2025 | Injectafer |
| Travere Therapeutics, INC. | $25.76 | 2024 | |
| Fresenius USA Marketing, INC. | $24.15 | 2025 | Velphoro |
| Ani Pharmaceuticals, INC. | $21.54 | 2023 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.47 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.36 | 2020 | |
| Apellis Pharmaceuticals, INC. | $14.93 | 2025 | Empaveli |
| Janssen Pharmaceuticals, INC | $14.67 | 2019 | |
| Novo Nordisk INC | $13.28 | 2024 | Rivfloza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wasae Tabibi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.